J.B. VermorkenW.W. ten Bokkel HuininkBreastSoo Lo , Stephen R.D. Johnston . (2003) Novel systemic therapies for breast cancer. Surgical Oncology 12 , 277-287 Online publication date: 1-Dec-2003. /Lo S, Johnston SRD. Novel systemic therapies for breast cancer. Surg Oncol. 2003;12:...
Many chemotherapy drugs used for treating breast cancer are given in liquid form, as intravenous (IV, into the vein) infusions or injections (into the skin), but some are available as pills or tablets.2 Some drugs may be given alone, and other drugs are combined to work together. When ch...
Gene therapy for breast cancer initially involves local or systemic delivery. Local delivery may be intrapleural or via direct injection to lesions. However, systemic delivery remains the greatest challenge with targeting, although methods using antibodies or growth factor receptor ligands have been demon...
Cancer Treatment Reviews 1: 183–203 (1974). Article Google Scholar Canellos, G.P.; Pocock, S.J.; Taylor, S.G.; Sears, M.E.; Klaasen, D.J. and Band, P.R.: Combination chemotherapy for metastatic breast cancer. Prospective comparison of multiple drug therapy with 1-phenylalanine ...
that can facilitate the seeding and growth of metastatic cancer cells in distant organs, but the effects of chemotherapy on tumour-derived EVs remain unclear. Here we show that two classes of cytotoxic drugs broadly employed in pre-operative (neoadjuvant) breast cancer therapy, taxanes and anthracyc...
Each class is additionally classified to sub-classes showing a list of different chemotherapeutic drugs used in specific treatment options. 1.2 Source of data Data from the available biomedical literature were reviewed and pooled to evaluate metastatic breast cancer treatment regarding their mechanisms, ...
Pharmacists in the U.S. are warning that hundreds of medications are in short supply. Among some of the most concerning are shortages of chemotherapy drugs and those needed for ADHD, like Adderall. CBS News medical contributor Dr. Céline Gounder, editor-at-large for public health at KFF, ...
Single immunotherapy fails to demonstrate efficacy in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC). Research on immune reactions before and after systemic agents for mCRC is warranted. Our study examined cell line models to compare the expression of immune surface marke...
in the 1980s, which substantially reduced 5-year recurrence rates (but had somewhat less effect on 5-year mortality rates), also substantially reduce 15-year mortality rates. Further improvements in long-term survival could well be available from newer drugs, or better use of older drugs. ...
The scheduled dosages of these three drugs and of the anthracyclines doxorubicin (A) and epirubicin (E) were used to define standard CMF, standard 4AC, and CAF and CEF. Log-rank breast cancer mortality rate ratios (RRs) are reported. Findings In trials adding four separate cycles of a ...